Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 6 Non-Muscle Invasive Bladder Neoplasms 5 Multiple Myeloma 4 Glioma 4 Prostatic Neoplasms 3 Neoplasms 3 Carcinoma, Transitional Cell 3 Wilms Tumor 2 Urothelial Cancer 2 Rhabdoid Tumor 2 Ovarian Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Esophageal Neoplasms 2 Ependymoma 2 Central Nervous System Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Acrocephalosyndactylia 2 Xanthogranuloma, Juvenile 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × erdafitinib × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡